Gengigel
Phase 1Small molecule
Gengigel is one of 19 small molecule programs targeting Pilot Study. It is currently in Phase 1.
1
Indications
2
Total Trials
2
Active Trials
18
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
27 competitors in Pilot Study
#DrugCompanyPhaseTrials
1Farxiga
AstraZenecaApproved
Doptelet
AAkarx
Approved
Glucophage
EMD SeronoPhase 2
CC-486
Bristol-Myers SquibbPhase 2
Atibuclimab
IImplicit Bioscience
Phase 2
Rapamycin
MMaastricht Radiation Oncology
Phase 1
Hytrin
AAbbott
Preclinical
Reyataz
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Preclinical
Lopinavir/ritonavir
AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Preclinical
Sonovue
BBracco Diagnostics, Inc
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Photobiomodulation Therapy1 trial
Testing the Efficacy of Photobiomodulation Therapy and Hyaluronic Acid Gel on Post-surgical Healing After Gingivectomy
Enrolling by invitation·—·Phase 1·NCT07169357·38 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Gengigel. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- UUniversity of Malaya